reviews glp-1 Scientist Bioma GLP1 Booster Medical Weight Loss NYC |
Description
4), which did not withstand the adjustment for weight loss (Supplementary Table 2)
Recent Phase 3 data showed average weight reduction exceeding 28% in some participant groups after extended treatment periods
Strategies for maintaining results after stopping Some people successfully maintain their results after discontinuing GLP-1 therapy
10.1016/S0140-6736(19)31271-1 Summary Keywords colorectal cancer, gastrointestinal cancer, GLP-1 receptor agonists, liver cancer, meta-analysis, obesity, oncological safety, pancreatic cancer Citation Wali AF, Rangraze I, Khan S, Mufti UB, El-Tanani M and Rizzo M (2026) Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies
